John Shumaker - Paragon 28 Executive US
| FNA Stock | USD 9.99 0.01 0.10% |
Executive
John Shumaker is Executive US of Paragon 28
| Address | 14445 Grasslands Drive, Englewood, CO, United States, 80112 |
| Phone | 855 786 2828 |
| Web | https://paragon28.com |
Paragon 28 Management Efficiency
The company has Return on Asset of (0.0839) % which means that on every $100 spent on assets, it lost $0.0839. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3371) %, meaning that it generated no profit with money invested by stockholders. Paragon 28's management efficiency ratios could be used to measure how well Paragon 28 manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.17. The current year's Return On Capital Employed is expected to grow to -0.12. At present, Paragon 28's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.34, whereas Total Assets are forecasted to decline to about 220.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Julie Andrews | Orthofix Medical | 53 | |
| Daniel JD | Orthopediatrics Corp | 54 | |
| Michael Pisetsky | Si Bone | 46 | |
| David JD | Pulmonx Corp | 63 | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
| Karen Aranki | Varex Imaging Corp | N/A | |
| Ahmet Tezel | LivaNova PLC | N/A | |
| Jennifer Englund | CVRx Inc | N/A | |
| Daniel Esq | CONMED | 60 | |
| MD FACS | Glaukos Corp | N/A | |
| Jill Mason | Orthofix Medical | N/A | |
| RN MBA | CVRx Inc | N/A | |
| Jeff Bertolini | Si Bone | N/A | |
| Brenton Taylor | Sight Sciences | 43 | |
| MSc MD | CVRx Inc | N/A | |
| Sarah Oliker | CONMED | 43 | |
| Andrew Senn | Integer Holdings Corp | 42 | |
| John Webb | LivaNova PLC | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Randy Waddell | Iradimed Co | N/A | |
| Aimee Einstein | Si Bone | N/A | |
Management Performance
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.0839 |
Paragon 28 Leadership Team
Elected by the shareholders, the Paragon 28's board of directors comprises two types of representatives: Paragon 28 inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paragon. The board's role is to monitor Paragon 28's management team and ensure that shareholders' interests are well served. Paragon 28's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paragon 28's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Jarboe, Executive Officer | ||
| Albert DaCosta, President, Chief Executive Officer, Co-Founder | ||
| B Johnson, Director | ||
| Kristina Wright, Independent Director | ||
| Matthew Brinckman, Senior Relations | ||
| Matt Jarboe, Chief Commercial Officer | ||
| Matt Brinckman, Senior Relations | ||
| Chadi Chahine, CFO Operations | ||
| Matthew Millard, Chief Officer | ||
| Frank Bono, Co-Founder, Chief Technology Officer | ||
| Jim Riegler, Co-Founder, Chief Financial Officer | ||
| Jeff Sears, Vice Operations | ||
| Erik Mickelson, Chief Controller | ||
| Krissy Wright, Director | ||
| Michelle Missal, VP Officer | ||
| Brendan Shook, Executive Vice President - Marketing and Medical Education | ||
| Stephen Deitsch, Chief Officer | ||
| Steve Deitsch, Principal Financial Officer | ||
| Francis Bono, Co-Founder, Chief Technology Officer | ||
| John Shumaker, Executive US | ||
| Hans Kestler, Executive International | ||
| Lee Rosenthal, Co-Founder, Vice President - National Accounts | ||
| Andrew Hill, Executive Development | ||
| Jonathan Friedman, General Secretary | ||
| Jason Edie, Chief Officer | ||
| Robert JD, General Secretary | ||
| Meghan Scanlon, Director |
Paragon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paragon 28 a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.0839 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 907 M | ||||
| Shares Outstanding | 83.72 M | ||||
| Shares Owned By Insiders | 40.56 % | ||||
| Shares Owned By Institutions | 60.95 % | ||||
| Number Of Shares Shorted | 4.52 M | ||||
| Price To Book | 5.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Paragon 28 offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Paragon 28's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Paragon 28 Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Paragon 28 Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Paragon 28. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Paragon Stock refer to our How to Trade Paragon Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Paragon 28. If investors know Paragon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Paragon 28 listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share 2.95 | Quarterly Revenue Growth 0.181 | Return On Assets (0.08) | Return On Equity (0.34) |
The market value of Paragon 28 is measured differently than its book value, which is the value of Paragon that is recorded on the company's balance sheet. Investors also form their own opinion of Paragon 28's value that differs from its market value or its book value, called intrinsic value, which is Paragon 28's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Paragon 28's market value can be influenced by many factors that don't directly affect Paragon 28's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Paragon 28's value and its price as these two are different measures arrived at by different means. Investors typically determine if Paragon 28 is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Paragon 28's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.